Sign In

Jacek Skarbinksi, MD

People

Kaiser Permanente Division of Research
2000 Broadway
Oakland, CA 94612

510-418-2196 (phone)
jacek.skarbinski@kp.org


Jacek Skarbinski, MD, is a research scientist at the Kaiser Permanente Division of Research and a practicing infectious diseases and HIV medicine specialist at Kaiser Permanente, Oakland Medical Center. In addition, he serves as the Program Director of the Kaiser Permanente Northern California HIV Fellowship. He is part of The Permanente Medical Group Physician Researcher Program and serves as co-chair of the Kaiser Permanente Northern California COVID-19 Clinical Research Coordinating Team.

Before joining The Permanente Medical Group in 2016, Dr. Skarbinski served with the Centers for Disease Control and Prevention (CDC) in various epidemiology and leadership roles. His CDC research addressed the epidemiology, diagnosis, treatment and prevention of infectious diseases with a focus on malaria, HIV, tuberculosis, and influenza. His current research interests include clinical trials, observational studies, and implementation science in a broad range of infectious diseases including HIV, tuberculosis, and COVID-19.

Dr. Skarbinski earned his MD at Stanford University School of Medicine after completing his BA at Cornell University. He completed his internal medicine residency at the University of California-San Francisco in the San Francisco General Internal Medicine Primary Care Track, served as an Epidemic Intelligence Service Officer at the CDC and completed an infectious diseases fellowship at Emory University School of Medicine.

Current Position(s):

  • Research Scientist III, Division of Research, Kaiser Permanente Northern California
  • Senior Physician, Department of Infectious Diseases, The Permanente Medical Group, Oakland Medical Center
  • Program Director, Kaiser Permanente Northern California HIV Fellowship

Section Affiliations:

Primary Research Interests:

  • HIV
  • Tuberculosis
  • COVID-19
  • Chronic fatigue syndrome
  • Clinical trials
  • Infectious diseases epidemiology
  • Delivery and implementation science

    A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) Treatment of COVID-19 in an Outpatient Setting

    This clinical trial will evaluate treatment with IV administered remdesivir in an outpatient setting in patients with COVID-19 who are at risk for disease progression.
    Investigator: Skarbinski, Jacek
    Funder: Gilead Sciences, Inc.

    SARS-CoV-2 Serological Antibody Testing for Disease Surveillance and Clinical Use

    This study will assess the sero-prevalence and sero-incidence of SARS-CoV-2 infection in Kaiser Permanente Northern California and assess correlates of exposure and immunity among KPNC members.
    Investigator: Skarbinski, Jacek
    Funder: National Cancer Institute
    No results found matching criteria

    Rationale and Design of the Pragmatic Randomized Trial of Icosapent Ethyl for High Cardiovascular Risk Adults (MITIGATE)

    Author(s): Ambrosy AP; Skarbinski J; Go AS; et al.

    Am Heart J. 2021 Jan 28.

    PubMed abstract

    Association of Mortality and Years of Potential Life Lost With Active Tuberculosis in the United States

    Author(s): Lee-Rodriguez C; Wada PY; Hung YY; Skarbinski J

    JAMA Netw Open. 2020 Sep 01;3(9):e2014481. Epub 2020-09-01.

    PubMed abstract

    Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization

    Author(s): Tartof SY; Skarbinski J; Murali SB; et al.

    Ann Intern Med. 2020 Aug 12.

    PubMed abstract

    Burden of Active Tuberculosis in an Integrated Health Care System, 1997-2016: Incidence, Mortality, and Excess Health Care Utilization

    Author(s): Wada PY; Lee-Rodriguez C; Hung YY; Skarbinski J

    Open Forum Infect Dis. 2020 Jan;7(1):ofaa015. Epub 2020-01-12.

    PubMed abstract

    Comparison of msp genotyping and a 24 SNP molecular assay for differentiating Plasmodium falciparum recrudescence from reinfection

    Author(s): Fulakeza J; McNitt S; Vareta J; Saidi A; Mvula G; Taylor T; Mathanga DP; Small DS; Skarbinski J; Gutman JR; Seydel K

    Malar J. 2019 Mar 18;18(1):84. Epub 2019-03-18.

    PubMed abstract

    Epidemiology, detection, and management of tuberculosis among end-stage renal disease patients

    Author(s): Okada RC; Barry PM; Skarbinski J; Chitnis AS

    Infect Control Hosp Epidemiol. 2018 11;39(11):1367-1374. Epub 2018-09-20.

    PubMed abstract